Responses
Therapeutics
Randomised controlled trial
Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors
Compose a Response to This Article
Other responses
No responses have been published for this article.